Received Apr 22, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RV5 | ROTAVIRUS (ROTATEQ) | MERCK & CO. INC. | 1 | — | — |
| RV5 | ROTAVIRUS (ROTATEQ) | MERCK & CO. INC. | 2 | — | — |
HCP reported that patient was administered the 1st and 2nd dose of ROTATEQ, but has not yet been administered the 3rd dose; No additional AE; This spontaneous report was received from a nurse and refers to a patient of unknown gender, 34-weeks-old at the time of reporting. The patient's medical history, concurrent conditions, and concomitant therapies were not reported. On an unknown date, the patient was vaccinated with the first and the second doses of Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ), Oral solution, 2 mL (route of administration, lot # and expiration date were not reported) for prophylaxis. Heath care professional (HCP) reported, that patient was administered the 1st and 2nd dose of Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ) on an unknown dates, but had not yet been administered the 3rd dose. At the time of reporting, the patient was beyond the recommended dosing age to be able to complete the series (inappropriate schedule of product administration). No symptoms reported, no additional adverse event (AE) was reported (no adverse event). Additional information is not expected.